Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06340737 · ClinicalTrials.gov registry record · Phase 1

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

A Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma, sponsored by Stanford University.

Recruiting
Registry status
Phase 1
Development phase
148
Enrollment target
1
Study location

NCT06340737 is a Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma that is actively recruiting participants, run by Stanford University. The registered enrollment target is 148 participants, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (44% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06340737, a Phase 1 study of Mantle Cell Lymphoma and Follicular Lymphoma, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
Phase 1
Development phase
148 participants
Enrollment target
1
Study location

Study Summary

This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and duration of response (DOR). An evaluable participant is one who completes leukapheresis, lymphodepleting chemotherapy and CART infusion.

Conditions Studied

Mantle Cell Lymphoma Follicular Lymphoma Marginal Zone Lymphoma Waldenstrom Macroglobulinemia Large B-cell Lymphoma Burkitt Lymphoma Lymphoplasmacytic Lymphoma Hairy Cell Leukemia

Interventions

  • DRUG CD22CART Infusion

Study Locations (1)

California

  • Stanford University - Palo Alto

Trial Details

FieldValue
Enrollment Target 148 participants
Start Date 2024-03-29
Est. Completion 2031-04
Phase Phase 1

Sponsor

Stanford University

1,744 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06340737

The ClinicalTrials.gov registry entry for NCT06340737 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (44% higher). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which CD22CART Infusion is the first listed.

NCT06340737 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06340737 about?

NCT06340737 is a clinical study titled "AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas". This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and d...

What is the current status of trial NCT06340737?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2024-03-29. Estimated completion is 2031-04.

What conditions does trial NCT06340737 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Large B-cell Lymphoma.

What interventions are being tested in trial NCT06340737?

The interventions under investigation include: CD22CART Infusion (DRUG).

Who is sponsoring clinical trial NCT06340737?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06340737 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mantle Cell Lymphoma

All registered trials for this condition

Follicular Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.